Selected Publications
Aziz MD, Shah J, Kapoor U, Dimopoulos C, Anand S, Augustine A, Ayuk F, Chaudhry M, Chen YB, Choe HK, Etra A, Gergoudis S, Hartwell MJ, Hexner EO, Hogan WJ, Kitko CL, Kowalyk S, Kröger N, Merli P, Morales G, Nakamura R, Ordemann R, Pulsipher MA, Qayed M, Reshef R, Rösler W, Schechter T, Schreiner E, Srinagesh H, Wölfl M, Wudhikarn K, Yanik G, Young R, Özbek U, Ferrara JLM, Levine JE.: Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant Leukemia : 2020.
Hartmann K, Gotlib J, Akin C, Hermine O, Awan FT, Hexner E, Mauro MJ, Menssen HD, Redhu S, Knoll S, Sotlar K, George TI, Horny HP, Valent P, Reiter A, Kluin-Nelemans HC: Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis. J Allergy Clin Immunol : 2020.
Freyer CW, Carulli A, Ganetsky A, Hughes ME, Krause TM, Timlin C, Frey NV, Gill SI, Hexner EO, Loren AW, Mangan JK, Martin ME, McCurdy SR, Perl AE, Pratz K, Porter DL, Luger SM.: Venous thromboembolism following pegaspargase in adults receiving antithrombin supplementation Leuk Lymphoma. : 2020.
Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, Mangan PA, Kulikovskaya I, Gupta M, Chen F, Tian L, Gonzalez VE, Xu J, Jung IY, Melenhorst JJ, Plesa G, Shea J, Matlawski T, Cervini A, Gaymon AL, Desjardins S, Lamontagne A, Salas-Mckee J, Fesnak A, Siegel DL, Levine BL, Jadlowsky JK, Young RM, Chew A, Hwang WT, Hexner EO, Carreno BM, Nobles CL, Bushman FD, Parker KR, Qi Y, Satpathy AT, Chang HY, Zhao Y, Lacey SF, June CH.: CRISPR-engineered T cells in patients with refractory cancer. Science : 2020.
Kim GYG, Burns J, Freyer CW, Hamilton KW, Frey NV, Gill SI, Hexner EO, Luger SM, Mangan JK, Martin ME, McCurdy SR, Perl AE, Porter DL, Schuster MG, Stadtmauer EA, Loren AW.: Risk of invasive fungal infections in patients with high-risk MDS and AML receiving hypomethylating agents. Am J Hematol. : 2020.
Yacoub Abdulraheem, Mascarenhas John, Kosiorek Heidi, Prchal Josef T, Berenzon Dmitriy, Baer Maria R, Ritchie Ellen, Silver Richard T, Kessler Craig, Winton Elliott, Finazzi Maria Chiara, Rambaldi Alessandro, Vannucchi Alessandro M, Leibowitz David, Rondelli Damiano, Arcasoy Murat O, Catchatourian Rosalind, Vadakara Joseph, Rosti Vittorio, Hexner Elizabeth, Kremyanskaya Marina, Sandy Lonette, Tripodi Joseph, Najfeld Vesna, Farnoud Noushin, Papaemmanuil Elli, Salama Mohamed, Singer-Weinberg Rona, Rampal Raajit, Goldberg Judith D, Barbui Tiziano, Mesa Ruben, Dueck Amylou C, Hoffman Ronald: Pegylated Interferon Alfa-2a for Polycythemia Vera or Essential Thrombocythemia Resistant or Intolerant to Hydroxyurea Blood : 2019.
Mascarenhas J, Kosiorek H, Prchal J, Yacoub A, Berenzon D, Baer M R, Ritchie E, Silver R T, Kessler C, Winton E, Finazzi M C, Rambaldi A, Vannucchi A M, Leibowitz D, Rondelli D, Arcasoy M O, Catchatourian R, Vadakara J, Rosti V, Hexner E, Kremyanskaya M, Sandy L, Tripodi J, Najfeld V, Farnoud N, Salama M E, Weinberg R S, Rampal R, Goldberg J D, Mesa R, Dueck A C, Hoffman R: A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis. Leukemia : 2019.
Linaburg Taylor, Davis Adam R, Frey Noelle V, Khawaja Muhammad R, Landsburg Daniel J, Schuster Stephen J, Svoboda Jakub, Li Yimei, Borovskiy Yuliya, Olson Timothy S, Bagg Adam, Hexner Elizabeth O, Babushok Daria V: Hodgkin lymphoma patients have an increased incidence of idiopathic acquired aplastic anemia. PloS one 14 (4): e0215021,2019.
Srinagesh HK, Özbek U, Kapoor U, Ayuk F, Aziz M, Ben-David K, Choe HK, DeFilipp Z, Etra A, Grupp SA, Hartwell MJ, Hexner EO, Hogan WJ, Karol AB, Kasikis S, Kitko CL, Kowalyk S, Lin JY, Major-Monfried H, Mielke S, Merli P, Morales G, Ordemann R, Pulsipher MA, Qayed M, Reddy P, Reshef R, Rösler W, Sandhu KS, Schechter T, Shah J, Sigel K, Weber D, Wölfl M, Wudhikarn K, Young R, Levine JE, Ferrara JLM.: The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease.
Blood Adv : 2019.
Soderquist, Craig R, Ewalt, Mark D, Czuchlewski, David R, Geyer, Julia T, Rogers, Heesun J, Hsi, Eric D, Wang, Sa A, Bueso-Ramos, Carlos E, Orazi, Attilio, Arber, Daniel A, Hexner, Elizabeth O, Babushok, Daria V, Bagg, Adam: Myeloproliferative neoplasms with concurrent BCR–ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 31 (5): 690-704,2018.
Academic Contact Information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-151
3400 Civic Center Boulevard
Philadelphia,
PA
19104
Phone: 215-662-6348
Patient appointments: 800-789-7366